Acumen Pharmaceuticals (ABOS) Interest & Investment Income (2021 - 2026)

Acumen Pharmaceuticals has disclosed Interest & Investment Income across 6 years of filings, most recently posting $1.1 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $1.1 million, down 56.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (down 52.75% YoY), and the FY2025 annual result was $7.4 million, down 47.98% from the prior year.
• Interest & Investment Income came in at $1.1 million for Q1 2026 at Acumen Pharmaceuticals, down from $1.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.0 million in Q1 2024 to a low of $76000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $1.9 million (2023), against an average of $2.1 million.
• Across the five-year window, Interest & Investment Income jumped 6400.0% in 2022 and sank 56.94% in 2026, its largest moves.
• Acumen Pharmaceuticals' Interest & Investment Income stood at $1.4 million in 2022, then surged by 183.84% to $4.0 million in 2023, then decreased by 24.27% to $3.0 million in 2024, then slumped by 55.82% to $1.3 million in 2025, then slipped by 19.52% to $1.1 million in 2026.
• The last three Interest & Investment Income figures came in at $1.1 million (Q1 2026), $1.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.